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Rifampin resistance inMycobacterium tuberculosis is largely determined by mutations in an 80-bp rifampin resistance deter-
mining region (RRDR) of the rpoB gene. We developed a rapid single-well PCR assay to identify RRDRmutations. The assay uses
sloppy molecular beacons to probe an asymmetric PCR of theM. tuberculosis RRDR by melting temperature (Tm) analysis. A
three-point Tm code is generated which distinguishes wild-type frommutant RRDRDNA sequences in approximately 2 h. The
assay was validated on synthetic oligonucleotide targets containing the 44 most common RRDRmutations. It was then tested on
a panel of DNA extracted from 589 geographically diverse clinicalM. tuberculosis cultures, including isolates with wild-type
RRDR sequences and 25 different RRDRmutations. The assay detected 236/236 RRDRmutant sequences as mutant (sensitivity,
100%; 95% confidence interval [CI], 98 to 100%) and 353/353 RRDRwild-type sequences as wild type (specificity, 100%; 95% CI,
98.7 to 100%). The assay identified 222/225 rifampin-resistant isolates as rifampin resistant (sensitivity, 98.7%; 95% CI, 95.8 to
99.6%) and 335/336 rifampin-susceptible isolates as rifampin susceptible (specificity, 99.7%; 95% CI, 95.8 to 99.6%). All muta-
tions were either individually identified or clustered into small mutation groups using the triple Tm code. The assay accurately
identified mixed (heteroresistant) samples and was shown analytically to detect RRDRmutations when present in at least 40% of
the totalM. tuberculosisDNA. This was at least as accurate as Sanger DNA sequencing. The assay was easy to use and well suited
for high-throughput applications. This new sloppy molecular beacon assay should greatly simplify rifampin resistance testing in
clinical laboratories.
Multidrug-resistant (MDR) and extensively drug-resistant(XDR)Mycobacterium tuberculosis is increasing worldwide (9,
27,37).Rapidmethods todetectdrugresistanceareneeded toquickly
identify drug-resistant strains and to implement appropriate therapy
(4, 16, 36).M. tuberculosis does not naturally contain plasmids, and
almost all cases of clinical drug resistance are caused by single-nucle-
otide polymorphisms (SNPs) or small insertions/deletions in rele-
vant genes (28). In the case of rifampin resistance, 95 to 98% of ri-
fampin-resistant clinical strains have mutations in the 80-bp
rifampin resistance determining region (RRDR) of theM. tuberculo-
sisRNApolymerase beta (rpoB) gene (9, 11, 12, 15, 20, 28). PCR and
probe-basedmolecular genotyping assays can be used to detect these
resistance-inducingmutations. Such genotypic assays are potentially
more rapid than labor-intensive culture-based drug susceptibility
tests. Genotypic drug susceptibility testing has shown good overall
concordance with the phenotypic antibiotic susceptibility tests of
MDR andXDR clinical strains (6), and in a recent study, a genotypic
test actually correlated better with clinical outcome than standard
phenotypic susceptibility testing (36). When combined with auto-
mated sample processing systems, such as the Xpert MTB/RIF test
(14), genotypic susceptibility tests can significantly reduce testing
turnaround time, increasingpatient notification rates anddecreasing
time to treatment (4, 32).
The Xpert MTB/RIF assay is one example of a genotypic test
that is being increasingly used to screen for rifampin resistance
(33). However, the single-use cartridge design of the Xpert assay
limits its use for laboratory-based high-throughput testing. Sev-
eral widely used reverse blot hybridization assays, such as the
INNO-LIPA Rif.TB assay (Innogenetics, Belgium) and the MTB-
DRplus (Hain, Germany) assay (1, 5, 15, 19, 21, 23, 29, 34), are
available for laboratory-based rifampin resistance screening; how-
ever, these assays are complicated by their open hybridization for-
mat. Open hybridization systems require a relatively cumbersome
work process, including rigorous physical separation of different
work areas (2, 23) due to the risk of handling open PCR amplicons
in a molecular diagnostic laboratory. Open systems also require a
relatively large number of probes to test for relevant resistance-
associated mutations. This requirement complicates assay chem-
istry and hybridization parameters. In contrast to reverse blot hy-
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bridization assays, melting temperature (Tm)-based assays enable
mutation detection in closed systems. These assays take advantage
of the fact that fully complementary strands of DNA have higher
melting temperatures than DNA heteroduplexes which contain
one or more nucleotide mismatches. Tm assays are well suited for
busy diagnostic laboratories, because they can be performed in
homogeneous closed systems without the risk of carryover ampli-
con contamination, are amenable to multiplexing, and are easily
adapted to a high-throughput format. Fluorescence resonance en-
ergy transfer (FRET) probes, dually labeled probes, TaqMan, and
molecular beacon probes have all been used in Tm assays to detect
drug resistance mutations in M. tuberculosis, as has the high-res-
olution Tm analysis (HRMA) of PCR products using DNA inter-
calating dyes (9, 10, 13, 18, 20, 24, 26, 27). However, M. tubercu-
losis drug resistance assays which useTm analysis have been largely
limited to tests of the most commonly encountered mutations
(20, 24, 27). We have previously shown that a new generation of
mismatch-tolerant probes, called sloppy molecular beacons
(SMBs), can be efficiently used to identify mutations in the M.
tuberculosis genome associated with fluoroquinolone resistance
(8). The assay had high sensitivity and specificity, and the thermo-
dynamic properties of SMBs made it possible to develop an assay
with easily interpretable Tm curves. The assay was also able to
detect fluoroquinolone resistance mutations in clinical samples
that contained mixtures of drug-susceptible and drug-resistant
DNA. We have now applied the same technology to detect rifam-
pin resistance inM. tuberculosis. Here, we show that our approach
enables the rapid, high-throughput, single-well detection of mu-
tations in the rpoB RRDR ofM. tuberculosis.We tested the ability
of the assay to detect 44 different rpoB mutations that have been
described previously to be associated with rifampin resistance,
and we validated its performance on a panel of clinical samples
representing a diverse collection in terms of geographical distri-
bution and the mutation types. The ability of the assay to specifi-
cally identify rifampin-resistant clinical strains and to detect het-
eroresistance was also evaluated, and its performance was
compared to conventional antibiotic susceptibility test results and
verified with targeted sequencing.
MATERIALS AND METHODS
Clinical DNA samples. Two clinical sample sets were tested to include a
wide variety of mutations and geographic origins. The first sample set
consisted of 440 sequentialM. tuberculosis isolates cultured from patients
enrolled in a natural history study ofMDR tuberculosis (NCT00341601 at
clinicaltrials.gov) in the NationalMasan Tuberculosis Hospital in Chang-
won, Republic of Korea, for which reliable conventional drug susceptibil-
ity tests and/or DNA sequencing of theM. tuberculosis RRDR were avail-
able. The second sample set consisted of 149 selected M. tuberculosis
cultures obtained from the WHO TDR Tuberculosis Specimen Bank,
maintained by the United Nations Children’s Fund/UNDP/World Bank/
WHO Special Program for Research and Training in Tropical Diseases,
which includes cultures from Africa, Asia, Australia, Europe, and Latin
America (8), for a total of 589DNA samples tested. TheTDR sampleswere
chosen to represent a wide repertoire of RRDR mutants and a broad
geographical distribution for both RRDR mutants and rifampin-suscep-
tible controls. Conventional rifampin susceptibility was performed using
the LJ proportions method with 40 g/ml used as the critical rifampin
concentration defining resistance (31). Rifampin resistance results were
available for 561 out of the 589 samples. The RRDR sequence, and inmost
cases the entire rpoB gene sequence, was available for all 589 isolates. We
resequenced a subset of RRDR mutants, representing all of the different
mutations tested in our study, to confirm the original DNA sequencing
results. The results of the DNA sequencing performed as part of this cur-
rent study were used in the rare event of discordance with the prior se-
quencing result. Each DNA sample was quantified with a Nanodrop mi-
crovolume spectrophotometer (Thermo Scientific), and 2 to 5 ng of the
DNA sample was used for PCR. All samples were independently coded
and randomly redistributed to blind the sample sequence and origin be-
fore performing each test assay. The results of the assay used in this inves-
tigation were not reported to the treating physicians and were not used to
guide treatment decisions.
DNA samples from human origin, NTM, and Gram-positive and
Gram-negative bacteria. Pure human genomic DNA obtained from the
ATCC repository (Manassas, VA); 121 clinical nontuberculous mycobac-
terial (NTM) cultures, representing 26 species, isolated from patients at
theNationalMasanTuberculosisHospital; a laboratory strain ofM. smeg-
matis; 18 NTM isolates obtained from the ATCC repository (Manassas,
VA), consisting of M. abscessus, M. scrofulaceum, M. celatum, M. haemo-
philum,M. asiaticum,M. kansasii,M. avium,M. flavescens,M. szulgai,M.
terrae, M. fortuitum, M. intracellulare, M. marinum, M. xenopi, M. ther-
moresistibile,M. simiae,M. trivial, andM.malmoense; and DNA extracted
from 18 species of Gram-negative and Gram-positive bacteria represent-
ing the most common bloodstream infections and nosocomial pathogens
obtained from various sources (7) were selected to test for analytical spec-
ificity. DNA was isolated from pure clinical strains by boiling a loopful of
culture in Instagene matrix solution (Bio-Rad). The DNA was quantified
as described above and tested using 100 to 400 ng for each PCR. To test for
the capability of the assay to detectM. tuberculosisRRDRmutations in the
presence of a 10-fold excess of background NTM DNA, 105 genome
equivalents ofM. tuberculosisDNA harboring common RRDRmutations
found in our study (516GTC, 526TAC, 531TTG, and 533CCG)wasmixed
with 106 genome equivalents of NTM DNA. Human DNA was tested in
105-fold excess above the level of the targetM. tuberculosis DNA.
SMBs and primers. A 172-bp fragment (nucleotides 1226 to 1397,
with numbering based on the gene start site according to the Escherichia
coli DNA nomenclature) containing the rpoB RRDR was amplified using
the target primer rpoB-F (5=-agacgttgatcaacatccg-3=) and the antisense
primer rpoB-R (5=-acctccagcccggcacgctcacgt-3=). These primers were de-
signed to be specific to theM. tuberculosis complex andwere verified by an
alignment ofM. tuberculosis and all of the NTM rpoB sequences available
in the GenBank database (http://www.ncbi.nlm.nih.gov/GenBank/).
Three SMBprobes, rpo1 (5=-tetramethylrhodamine-cgaccgCccatgaattggct
cagctggctggtgAcggtcg-BHQ2-3=), rpo2 (5=-cyanine 5-ggcgcgaaccAcgacag
cgggttgttctggtccatgaacgcgcc-BHQ2-3=), and rpo3 (5=6 carboxyfluoresc
ein-cgcgcgcaTcAccAacagtcggTgcttgtgggtcaacccgcgcg-BHQ1-3=) (where
the underlined boldface sequences represent the stemportion of the SMB,
the lowercase sequences represent the probe portion of the SMB, upper-
case letters represent the mutations introduced into the probe region to
obtain a stable stem-loop structure, and BHQ represents Black Hole
Quencher), were targeted against the rpoB RRDR. The SMBs were de-
signed using the in silicoDNA folding program at http://mfold.rna.albany
.edu/?qmfold/dna-folding-form, and the probe-target hybrid folding
program at http://mfold.rna.albany.edu/?qDINAMelt/Two-state-melting
was used to predict the possible probe-target hybrid structures and Tms.
The probes were designed to generate a maximum Tm difference be-
tween wild-type and mutant sequences in their respective target re-
gions of the RRDR so as to enable their unambiguous identification.
Primers were obtained from Sigma Genosys, and the SMB probes were
from Biosearch, CA.
Using artificial oligonucleotides containing rpoB RRDRmutations
to test assay probes. Not all of the RRDR mutations described in the
literature were available to us in the form of clinicalM. tuberculosisDNA.
To enable us to test the assay against the broadest range of RRDR muta-
tions, we created oligonucleotides containing either wild-type or mutant
RRDR sequences, including 44 clinically relevant mutations identified as
being present at a frequency of at least 0.1% in clinical settings (based on
an extensive literature search), to test the ability of the assay probes to
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identify different RRDR sequence types. The 44 differentmutations span-
ning the RRDR from codons 507 to 533 included SNPs, insertions, and
double mutants (Table 1). The Tm of each of the three SMB probes in the
presence of each RRDR oligonucleotide target was measured. Approxi-
mately 500 ng of individual oligonucleotide targets was added to a reac-
tion mixture containing 0.8 ng/l of each SMB probe, 4 mM MgCl2, 1
PCRbuffer (10 Stoffel Buffer; Applied Biosystems), and 5%glycerol.Tm
analysis was performed using a Light Cycler 480 II real-time PCR system
(Roche Molecular Systems Inc.) using the following assay parameters;
denaturation at 95°C for 5 min, followed by cooling down to 45°C and
then gradual heating to 85°C,with continuousmonitoring of fluorescence
during the process at a rate of 10 data acquisitions per degree centigrade.
Tm calls were performed at the end of the reaction using the automatedTm
calling software (Light Cycler 480 software), and resulting Tm values for
each probe were determined. The three Tm values (one for each SMB
probe) that were generated in the presence of an RRDR target where then
used to define a three-point Tm code for each RRDRmutant or wild-type
sequence.
Sloppy molecular beacon Tm assay on clinical DNA. All PCR-Tm
analyses of DNA from clinical samples were performed and decoded by
two experimenters who were blinded to the nature and identity of the
samples. Each DNA sample was quantified using a Nanodrop microvol-
ume spectrophotometer (Thermo Scientific), and 2 to 5 ng of the DNA
sample was used for each PCR except where indicated otherwise. PCRwas




Tm (°C) of: dTm (°C) of:
No. Name rpo1 rpo2 rpo3 rpo1 rpo2 rpo3
1 WT 76.0 75.3 71.2
2 507 GGC-GAC 71.3 75.2 71.2 4.7 0.0 0.0
3 510 CAG-CAC 69.7 74.4 71.9 6.3 0.8 0.7
4 511 A CTG-CCG 70.7 75.0 71.3 5.2 0.2 0.1
5 511 B CTG-CGG 71.3 75.0 71.4 4.7 0.3 0.2
6 512 AGC-ACC 70.7 75.2 71.4 5.3 0.1 0.3
7 513 A CAA-AAA 70.9 75.0 71.2 5.1 0.3 0.0
8 513 B CAA-CCA 71.1 74.9 71.6 4.9 0.4 0.4
9 513 C CAA-CTA 71.1 74.9 71.6 4.9 0.4 0.4
10 514 A TTC insertion 71.3 75.7 71.3 4.7 0.5 0.1
11 514 B TTC-TTG 70.2 74.5 71.0 5.8 0.8 0.1
12 514 C TTC-TTT (silent) 70.5 74.5 71.0 5.5 0.8 0.2
13 515 ATG-ATT 73.5 72.5 71.7 2.5 2.8 0.5
14 516 A GAC-GTC 75.6 71.3 71.4 0.4 7.0 0.2
15 516 B GAC-TAC 74.8 72.1 71.4 1.2 3.2 0.2
16 516 C GAC-GGC 77.0 73.0 71.3 01.0 2.3 0.1
17 516 D GAC-GCC 75.4 71.8 71.5 0.6 3.5 0.3
18 516 E GAC-TTC 75.1 71.4 71.5 0.9 3.9 0.4
19 516 F GAC-AAC 74.9 72.6 71.2 1.1 2.7 0.1
20 517 CAG-CTA 75.2 67.3 72.0 0.8 8.0 0.8
21 518 AAC-TAC 74.9 70.0 71.7 1.1 5.3 0.6
22 522 A TCG-TTG 76.2 73.2 70.2 0.2 2.1 1.0
23 522 B TCG-CCG 75.1 71.9 72.5 0.9 3.4 1.3
24 522 C TCG-TGG 76.0 72.4 71.2 0.0 2.9 0.1
25 526 A CAC-TAC 76.0 75.2 65.8 0.0 0.1 5.4
26 526 B CAC-GAC 75.7 75.0 64.1 0.3 0.3 7.1
27 526 C CAC-CGC 75.8 75.0 67.9 0.2 0.3 3.3
28 526 D CAC-CTC 76.4 75.4 65.0 0.5 0.1 6.2
29 526 E CAC-CAG 76.3 75.3 65.1 0.3 0.1 6.1
30 526 F CAC-AAC 75.9 75.1 65.7 0.0 0.2 5.5
31 526 G CAC-TGC 75.1 75.6 63.0 0.9 0.4 8.1
32 526 H CAC-CCC 76.3 75.1 64.0 0.3 0.2 7.2
33 526 I CAC-ACC 76.0 75.2 62.9 0.1 0.1 8.3
34 527 AAG-AGG 76.0 75.2 67.6 0.0 0.1 3.6
35 529 CGA-CAA 76.6 75.3 65.5 0.6 0.0 5.7
36 531 A TCG-TTG 75.2 75.4 74.7 0.8 0.1 3.5
37 531 B TCG-TGG 75.5 75.4 73.8 0.4 0.2 2.6
38 531 C TCG-GCG 76.2 75.5 71.9 0.2 0.2 0.7
39 531 D TCG-TAC 76.3 75.4 74.0 0.3 0.2 2.8
40 531 E TCG-CAG 75.5 75.7 74.9 0.5 0.4 3.8
41 531 F TCG-TAG 75.4 75.3 72.7 0.6 0.1 1.5
42 533 A CTG-CCG 75.6 75.6 72.1 0.4 0.3 1.0
43 533 B CTG-ATG 74.7 75.6 73.3 1.3 0.3 2.1
44 514, 531 TTC-TTT, TCG-TTG 71.1 75.7 74.9 4.9 0.4 3.7
45 516, 522 GAC-GGC, TCG-TTG 77.5 69.8 70.7 01.5 5.5 0.5
a Each Tm value represents an average of 10 separate reactions. WT, wild-type RRDR sequence. The shaded cells represent the dTm values obtained for the probes detecting the
corresponding mutations.
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performed in 384-well plates using a Roche Light Cycler 480 II real-time
PCR system (Roche Molecular Systems Inc.) in 20-l reaction volumes
containing 1 M target primer and 50 nM antisense primer, 0.8 ng/l of
each SMB probe, 4 mM MgCl2, 250 mM deoxynucleoside triphosphates
(dNTPs), 1 PCR buffer, 5% glycerol, 0.06 U/l of AmpliTaq Gold Stof-
fel DNA polymerase (Applied Biosystems), and 2 to 5 ng of sample DNA
or an equivalent volume of water. PCR was carried out with the following
steps: activation of the enzyme for 2 min at 95°C, followed by 45 cycles of
denaturation at 95°C for 15 s, annealing at 65°C for 30 s, and extension at
72°C for 10 s. Following PCR cycling, post-PCR-Tm analysis was per-
formed by denaturation at 95°C for 5 min, followed by cooling down to
45°C and then gradual heating to 85°C, with continuous monitoring of
fluorescence during the process at a rate of 10 data acquisitions per degree
centigrade. Tm calls were performed at the end of the reaction using the
automated Tm calling software (Light Cycler 480 software), and resulting
Tm values for each probe were determined. A nontemplate control using
sterilewater instead ofDNAas the templatewas used as theDNA-negative
control, and a DNA-positive control using 1 ng of genomic DNA fromM.
tuberculosisH37Rv as the template was also included in each assay plate.
Assay LOD. The analytical sensitivity of the assay was determined
using serial dilutions of three different genomic DNA samples. One sam-
ple had a wild-type RRDR sequence, and one sample each had the RRDR
mutations 516GTC and 531TTG, which were chosen because these two
mutations occurred frequently in our clinical DNA panel and in the liter-
ature. Each DNA sample was serially diluted to represent a concentration
range from 106 to 10 genome equivalents per reaction. The rpoB SMB
assay was performed 10 times at each dilution, and the minimum DNA
concentration which produced correct Tm codes 100% of the time was
determined as the limit of detection (LOD) of the assay for that RRDR
type.
DNA mixtures containing wild-type and 531TTG mutant DNA.
DNA mixtures containing wild-type and mutant DNA were prepared to
evaluate the performance of the assay in mixed samples containing both
wild-type and RRDR mutant DNA (heteroresistance). This situation
might occur clinically in a dual M. tuberculosis infection or during the in
vivo evolution of rifampin resistance caused by tuberculosis treatment
(17). Various amounts of the 531TTGmutant genomic DNA (a representa-
tive highly prevalentRRDRmutation)was added towild-typeM. tuberculosis
DNA to generateDNAmixtures containing 10 to 90%mutantDNA (in 10%
increments) in a total DNA amount of 10 ng (106 genome equivalents). SMB
Tm shift assays and Sanger sequencing of the RRDRwere performed on each
mixedDNA type to compare the ability of the SMB assay to detect the RRDR
mutant in this mixture to that of Sanger DNA sequencing.
Sanger DNA sequencing. DNA samples were amplified using rpoB
gene-specific primers as described above, except for the fact that 0.5 M
both forward and reverse primers, 2.5 mM MgCl2, and 0.03 U/l of
AmpliTaq Gold DNA polymerase (Applied Biosystems) were used. The
amplified products were checked by gel electrophoresis and then purified
using a PCR purification kit (Qiagen) by following the manufacturer’s
instructions. The purified PCR products were subjected to bidirectional
sequencing using the rpoB gene-specific forward and reverse primers in a
3130XL Genetic Analyzer (Applied Bio-systems) using a BigDye Termi-
nator, version 3.1, cycle sequencing kit (Applied Biosystems) according to
the manufacturer’s instructions.
Human subject approval. This study was approved by the National
Masan Tuberculosis Hospital, NIAID, and UMDNJ institutional review
boards, and all subjects gave written informed consent (UMDNJ IRB
protocol number 0120090104).
RESULTS
SMB design parameters produce a gradient of Tm values which
differentiate mutant fromwild-type RRDR sequences.We have
previously demonstrated the utility of SMB Tm-based assays to
detect fluoroquinolone resistance-associated mutations inM. tu-
berculosis (8). To identify rifampin resistance-associated muta-
tions in theM. tuberculosisRRDR, we designed three SMB probes,
rpo1, rpo2, and rpo3, which contained 28- to 32-bp probe se-
quences and 5- to 6-bp stem sequences. The probes were designed
to generate stable stem-loop structures while avoiding the forma-
tion of secondary structures in the loop region. The rpo1 probe
targeted RRDR codons 507 to 516, rpo2 targeted codons 514 to
523, and rpo3 targeted codons 524 to 533. Each probe was de-
signed to specifically detect all clinically relevant resistance-asso-
ciated RRDR mutations spanning the codons targeted by the re-
spective probes. A stable stem-loop structure is necessary for
optimal binding kinetics between the SMB probes and the M.
tuberculosis DNA target and for the production of distinct Tm
values corresponding to each RRDR mutation. We stabilized the
stem-loop structures for all three probes by introducing muta-
tions into the probe loop to disrupt secondary structures and pal-
indromes (Fig. 1A) as described previously (7, 8). The mutations
introduced were chosen either to be complementary to a known
FIG. 1. Probe structures and Tm profiles against artificial targets. (A) The
stable stem-loop structures of the three SMB probes used in the assay are
shown. Related and unrelated mutations in the loop region introduced to
obtain a stable stem-loop structure are shown in blue uppercase letters. Up-
percase letters in black show the stem regions. (B) Three-probe Tm code of the
assay tested against artificial targets with the wild-type RRDR or knownRRDR
mutations. Each horizontal line containing a square, circle, and triangle rep-
resents a unique 3-point Tm code corresponding to a single RRDR sequence.
Line 1 shows results for a wild-type RRDR target, and lines 2 to 45 show results
formutantRRDR targets. The sequences of themutations tested correspond to
those shown in rows 1 to 45 of Table 1. Mutants are detectible by the presence
of a substantial shift in the Tm value of either one or more of the three Tm
points. Lines 2 to 12 show RRDR sequences harboring mutations in codons
507 to 514. Lines 13 to 24, RRDR sequences harboring mutations in codons
515 to 522; lines 25 to 35, RRDR sequences harboringmutations in codons 526
to 529; lines 36 to 43, RRDR sequences harboring mutations in codons 531 to
533; lines 44 and 45 show two RRDR double mutants.
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RRDR mutation or to be unrelated to any known nucleotide at
that position, depending on assay requirements and on the result-
ing probe structure. Among the rifampin resistance-associated
mutations introduced, probe rpo1 included a 516GGC mutation
instead of wild-type sequence and rpo3 included 531TTG and
533ATG mutations instead of wild-type sequence. The inclusion
of RRDR resistance-associated mutations within the SMB probes
produced a gradient of probe-target relatedness, with certain
commonRRDRmutations producingTm values higher thanwild-
type RRDR values and other (less commonly occurring) RRDR
mutations producing Tm values lower than that of wild-type
RRDR (Table 1 and Fig. 1B).
Wemeasured the Tm of all three SMBs in the presence of wild-
type RRDR and each of the RRDR mutant targets using artificial
oligonucleotides. A three-point Tm code for each oligonucleotide
target was generated by this procedure (Table 1). We found that
the Tm code for the wild-type target could be distinguished from
RRDRmutant targets in all cases. For 41 of the 44 RRDRmutants,
at least one of the three SMBs had aTm value difference (dTm) of at
least 2.1°C from the wild-type RRDR value (Table 1 and Fig. 1B).
Many dTms were even higher. Targets containing commondouble
mutants also had at least one probe with a dTm of at least 2.1°C
(Table 1 and Fig. 1B). Three less commonly occurring RRDRmu-
tations, 531GCG, 531TAG, and 533CCG,were detectedwith dTms
of0.7,1.5, and1.0°C, respectively. However, these mutants
produced larger dTms when chromosomal DNA from clinical M.
tuberculosis isolateswas tested (describedbelow).TheRRDRmutants
could also be conveniently grouped into Tm code clusters corre-
sponding to the codons tested by the individual probes (Fig. 1B and
Fig. 2).
Assay Tm profiles of clinical samples compared to DNA se-
quencing. We evaluated the ability of the SMB assay to detect
RRDRmutations against a panel of 589 clinical samples of diverse
geographical origins (Table 2). The test panel included 236 RRDR
mutant samples and 25 different RRDR mutation genotypes dis-
tributed over 11 codons, including the common clinical muta-
tions, double mutants, codon insertions, and deletions (Table 2).
The predominant mutation type was 531TTG (62%), followed by
516GTC (8.8%), 526TAC (7%), and 533CCG (4%), with the
other genotypes being contained in the remaining 18% of the
RRDR mutants. The assay identified 236/236 (sensitivity, 100%;
95% confidence intervals [CIs], 98.0 to 100.0%) RRDR mutants
correctly, including 234/234 samples that contained only mutant
DNA and 2/2 samples that were identified as heteroresistant
mixed infections, by DNA sequencing. For 24 out of the 25 muta-
tions, the average dTm values were between 2.4 and 9.7°C, as either
a positive or a negative shift from the Tm of the wild-type se-
quence, for at least one of the three probes (Table 2). The 10
samples with a 533CCGmutation had dTms ranging from1.0 to
1.5°C. Thus, our tests of clinical samples identified all RRDR
mutants, in contrast to our tests of oligonucleotides where 3/44
RRDRmutations showed smaller dTms, making themmore diffi-
cult to detect. Assay specificity was also high, with 353/353 (100%;
95%CI, 98.7 to 100.0%) samples with wild-type RRDR sequences
being correctly identified as having wild-type RRDR by the SMB
assay. The 353 wild-type samples had mean dTm values for
rpo1, rpo2, and rpo3 of 69.7  0.18, 69.7  0.21, and 64.9 
0.29°C, respectively (Table 2).
All of the wild-type and mutant DNA samples generated an
identifiable three-Tm code, which enabled the grouping of the
FIG. 2. Three-pointTm profile of 589 clinical DNA study samples. The results of the assay tested against the clinicalM. tuberculosis study isolates are shown. The
horizontal green, pink, and light-blue lines represent the Tm zones corresponding to the wild-type RRDR sequence for each of the three individual probes.
Samples with one or more of the three Tm values that fall outside these Tm zones are easily identified as rifampin resistant. Rifampin-susceptible and rifampin-
resistant isolates can be distinctly clustered based on their individualTm profiles, as shown enclosedwithin the orange and blue rectangles. The red circle indicates
the samples with the 533CCG mutation, which was distinctly and independently clustered from the wild-type samples in spite of having a relatively low dTm
value. The purple circle indicates the three rifampin-resistant samples with mutations in the rpoB gene outside the RRDR.
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RRDR mutants into smaller clusters that contained one or more
possible mutations as observed with the artificial targets (Fig. 2
and Table 2). Specifically, the assay clustered single mutants, in-
sertions, and deletions into the following groups: 511/513mutant,
513-514CAA insertion, 516AAC/522TTG, 516GTC, 516CTC,
516TAC, 516GGC, 518AAC deletion, 526CGC, 526TGC/CTC/
TAC, 526GAC, 531CAG/TTG, 531TGG, and 533CCG (Table 2
and Fig. 1B). Double mutants were identified by the presence of
characteristic dTms from more than one probe (Table 2).
Comparison to phenotypic drug susceptibility testing. The
performance of the rpoB SMB assay was compared to phenotypic
drug susceptibility testing in the 561 samples for which rifampin
drug susceptibility testing results were available (Fig. 2). Sensitiv-
ity for resistancewas 222/225 (98.7%; 95%CI, 95.8 to 99.6%), and
specificity was 335/336 (99.7%; 95% CI, 98.1 to 99.9%). Among
the rifampin-resistant false negatives, three contained rpoBmuta-
tions outside the RRDR (251TTC, 331CCC, and 572TTC). The
single rifampin-resistant false positive occurred in a sample that
was found to have an rpoB 511CCG mutation upon DNA se-
quencing. Clinical isolates with 511CCG mutations are prone to
be misreported as rifampin susceptible by phenotypic rifampin
susceptibility assays (31). Thus, this particular clinical strain may
have been truly rifampin resistant. In fact, two other isolates in our
study with the 511CCG mutation were reported to be phenotyp-
ically rifampin resistant. Unfortunately, cultures of this isolate
were not available for repeat phenotypic susceptibility testing. The
SMB assay and phenotypic drug susceptibility results were con-
cordant for all of the other 557 samples tested.
Analytical specificity of the assay. The analytical specificity of
the assay was further tested usingDNA extracted from 121 clinical
and 18 reference strains and 1 laboratoryNTM strain, as well as 18
species of Gram-positive andGram-negative bacteria. None of the
NTMs, except for M. malmoense, generated a perceptible signal
from any of the 3 probes. Very high concentrations of M. mal-
moense DNA (100 to 200 ng) caused the rpo2 probe to generate a
Tm of 70°C, but no measurable Tm values were generated for the
rpo1 and rpo3 probes.M. smegmatis also generated a profile sim-
ilar to that ofM. malmoense which is an rpo2 Tm of 70°C, even at
lower DNA concentrations of up to 1 ng. This triple-Tm code (0,
70, and 0) was quite distinct from all of the other Tm codes that we
had obtained on tests of both wild-type and mutant RRDR M.
tuberculosis DNA. None of the Gram-positive or Gram-negative
bacteria tested produced a measurable signal. To test for possible
interference from NTM DNA, we mixed 106 genome equivalents
of M. malmoense, M. abscessus, M. avium, M. chelonae, M. gor-
donae,M. intracellulare,M. kansasii, andM. smegmatisDNAwith
105 genome equivalents ofM. tuberculosisDNA containing RRDR
mutations at 516GTC, 526TAC, 531TTG, or 533CCG. Each
RRDRmutant was correctly identified despite the presence of ex-
cess NTMDNA (see Table S1 in the supplemental material). Fur-
ther increasing the M. malmoense DNA concentration to a 20- to
50-fold excess compared to the concentration of M. tuberculosis
DNA caused the rpo2 probe to generate a double Tm peak in the
presence of the M. tuberculosis 516GTC and 516AAC RRDR mu-
tants (see Table S1).When a double peakwas visualized, one of the
double peaks corresponded to the Tm expected for the M. tuber-
TABLE 2 Three-probe Tm (°C) code of the assay in tests of clinical M. tuberculosis DNA
a
Sample Tm (
°C) of: SD for probe no.: dTm (
°C) for probe no.:
No. of
isolatesNo. Mutation type rpo1 rpo2 rpo3 1 2 3 1 2 3
#1 Wild type 69.7 69.7 64.9 0.18 0.21 0.29 353
2 511CTG-CCG 65.0 69.6 64.8 0.70 0.60 0.55 4.6 0.1 0.0 3
3 513CAA-CTA 65.9 69.8 64.7 0.64 0.35 0.51 3.8 0.1 0.1 2
4 513CAA-AAA 65.7 69.8 64.7 0.11 0.16 0.43 4.0 0.1 0.2 2
5 513-514CAA insertion 64.4 68.9 64.5 0.00 0.00 0.00 5.3 0.8 0.4 1
6 516GAC-AAC 69.8 67.7 65.1 0.00 0.00 0.00 0.1 2.0 0.2 1
7 516GAC-GTC 69.3 65.4 64.9 0.44 0.50 0.49 0.4 4.3 0.0 21
8 516GAC-CTC 67.6 62.9 64.5 0.00 0.00 0.00 2.1 6.8 0.4 1
9 516GAC-TAC 68.3 64.7 64.5 0.36 0.33 0.87 1.4 5.0 0.4 7
10 518AAC deletion 69.8 62.9 65.3 0.00 0.00 0.00 0.1 6.8 0.4 1
11 522TCG-TTG 69.7 66.8 64.3 0.00 0.00 0.00 0.0 2.8 0.5 1
12 526CAC-CGC 69.8 69.9 60.0 0.00 0.20 0.01 0.2 0.2 4.9 4
13 526CAC-TGC 69.8 70.1 59.5 0.00 0.00 0.00 0.1 0.4 5.4 1
14 526CAC-CTC 69.8 69.4 58.9 0.18 0.50 0.56 0.2 0.3 5.9 3
15 526CAC-TAC 69.6 69.6 59.0 0.34 0.30 0.14 0.1 0.1 5.9 17
16 526CAC-GAC 69.8 69.7 58.3 0.08 0.44 0.17 0.1 0.0 6.5 4
17 531TCG-CAG 69.9 69.9 68.6 0.01 0.02 0.06 0.2 0.2 3.7 2
18 531TCG-TTG 69.8 69.6 68.6 0.55 0.53 0.42 0.1 0.0 3.7 147
19 531TCG-TGG 70.0 69.9 67.3 0.00 0.00 0.00 0.3 0.2 2.4 1
20 533CTG-CCG 69.8 69.8 66.1 0.18 0.14 0.23 0.1 0.1 1.2 10
21 513CAA-CTA, 523GGG-GAG 65.8 68.0 64.4 0.00 0.00 0.00 3.9 1.7 0.5 1
22 515ATG-ATT, 516GAC-TAC 66.7 64.8 64.4 0.00 0.00 0.00 3.0 4.9 0.5 1
23 515ATG-GTG, 516GAC-GGC 70.2 66.3 65.1 0.00 0.00 0.00 0.5 3.4 0.2 1
24 516GAC-GGC, 518AAC-CAC 68.5 59.9 65.4 0.00 0.00 0.00 1.2 9.7 0.5 1
25 516GAC-TAC, 531TCG-TTG 68.2 64.1 68.3 0.00 0.00 0.00 1.5 5.5 3.4 1
26 516GAC-GGC, 533CTG-CCG 72.2 67.9 66.2 0.23 0.19 0.31 2.5 1.8 1.4 2
a SD represents the standard deviations of the Tm values of each of the three probes for the different clinical samples harboring the same RRDR mutations. The shaded cells
represent the dTm values obtained for the probes detecting the corresponding mutations.
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culosis RRDRmutant, and the other peak corresponded to the Tm
expected forM.malmoenseDNA (data not shown).M.malmoense
DNA alone, when used at a 20- to 50-ng concentration, generated
a single peak with a Tm of 70°C corresponding to the rpo2 probe,
and this did not mimic the wild-type profile or any of the RRDR
mutant three-probe Tm profiles (see Fig. S1A in the supplemental
material). Results identical to those for M. malmoense were ob-
tained when 10 ng of the laboratory strain of M. smegmatis DNA
was spiked intoM. tuberculosis DNA containing the 516GTC and
516AAC mutations (see Table S1). These results strongly suggest
that NTM coinfections will not affect assay results regarding M.
tuberculosis rifampin susceptibility. The assay was also found to be
unaffected by the presence of as much as a 105-fold excess of hu-
man genomic DNA compared to the concentration of M. tuber-
culosis DNA. The assay’s capacity for mutation detection also re-
mained unaltered, as tested with a mixture containing a large
excess of human DNA mixed with clinical sample DNA contain-
ing the RRDRmutation 516TAC, suggesting that human genomic
DNA from sputum should not interfere with the assay’s perfor-
mance (see Fig. S1B).
Assay LOD. Genomic DNA from M. tuberculosis containing
wild-type rpoB RRDR and the two most common RRDR muta-
tions, 516GTCand 531TTG,were chosen to determine the limit of
detection of the rpoB SMB assay. DNA samples were serially di-
luted from 10 ng to 100 fg per microliter in 10-fold decrements,
and the SMB assay was performed on 2 l of each individual
dilution 10 times. We observed that the Tm values obtained at
different concentrations were independent of the initial amount
of target DNA put into the reaction forM. tuberculosis with wild-
type (Fig. 3A) and mutant RRDR (data not shown), when Tm
peaks could be measured. Each probe had a characteristic LOD
below which no Tm value could be observed.We defined the assay
LOD as the DNA concentration below which at least one probe
could not consistently measure a Tm (probe rpo3 in this case). For
the wild-type andmutant DNA samples, the assay could detect 20
and 2 pg ofDNAcorrectly 100%of the time (Fig. 3B), respectively,
which is approximately 2,000 and 200 M. tuberculosis genome
equivalents, respectively. These results suggest that the assay is
able to detect rifampin resistance in DNA extracted from all
smear-positive and many smear-negative patient samples.
Detection of 531TTGmutation inDNAmixtures.The ability
of the rpoB SMB assay to detect the RRDRmutant in this mixture
was compared to that of Sanger DNA sequencing. The SMB assay
detected the presence of the RRDR mutation down to a concen-
FIG. 3. Analytical sensitivity of the assay. (A) Assay curves with limiting amounts of wild-typeDNA target.Melting temperature profiles of the three SMBprobes
on serial dilutions of M. tuberculosis H37Rv genomic DNA with wild-type rpoB RRDR. (B) Limit of detection (LOD) of the assay against wild-type and RRDR
mutant DNA. Tm values for each probe are shown for assays performed against the wild-type RRDR and two different RRDRmutant DNA samples. Assays were
tested with a range of DNA concentrations as indicated. The LOD of the assay for each RRDR sequence type is defined by the LOD of the probe with the lowest
analytical sensitivity. As shown, the LOD for wild-type RRDR was 20 pg, and the LOD for the 516GTC and 531TTG mutant RRDR samples was 2 pg.
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tration of 40%mutantDNA, as indicated by the double peak ofTm
values (Fig. 4). The mutant Tm peak became increasingly promi-
nent as more mutant DNAwas present in the mixture. DNAmix-
tures with 10, 20, and 30%mutantDNA showed a single wild-type
Tm peak and were indistinguishable from a sample containing
100% wild-type DNA (Fig. 4). Using the same DNA mixtures to
perform the bidirectional sequencing of the rpoB amplicon, the
unequivocal presence of the mutant DNA was apparent only on
sequencing chromatograms when at least 50% mutant DNA was
present. Thus, our SMB assay detected mixed infections at least as
well as Sanger DNA sequencing as far as the most common
531TTG mutation was concerned.
DISCUSSION
The assay used in this study detected the reported RRDR muta-
tions with high sensitivity and specificity. The assay was also ana-
lytically very specific forM. tuberculosiswhen tested against a large
panel of NTM and other bacteria. Heteroresistance was detected
at least as well as that detected by SangerDNA sequencing. Finally,
the assay LOD appeared to be sufficiently sensitive for use in all
smear-positive and many smear-negative sputum samples from
tuberculosis patients. To our knowledge, our study describes the
first Tm shifting assay for rifampin-resistant M. tuberculosis with
this high a level of performance. The mismatch-tolerant SMB
probes used in this study offer several advantages over the current
generation of probe-based drug susceptibility tests. Unlike open
hybridization assays, our assay is performed in a closed system,
which greatly simplifies sample testing and minimizes cross-con-
tamination. Unlike HRMA detection methods, which detect mu-
tations by recognizing subtle melting curve variants (9, 27), our
assay produces clear and consistent Tm peaks, which enables
highly reproducible Tm value identification.
Several assays have been described previously which utilize
FRET probes or dually labeled probes and post-PCR Tm shifts to
identify resistance-associated mutations (9, 10, 13, 18, 20, 24, 26,
27). A recent study by Luo et al. used dually labeled probes and a
common fluorophore to label and identify mutations associated
with isoniazid and rifampin resistance using Tm curve patterns,
which is similar to our approach. However, the dually labeled
probes used by those authors produced overlappingTm peaks that
are potentially difficult to analyze (24). This system is also unlikely
to be able to identifymostmixtures of wild-type andmutantDNA
sequences. In contrast, the peaks generated by SMBs were sharp
and consistent even when our assay was performed starting from
very small numbers of genomic DNA copies. Assays which use
FRET probes are constrained by the requirement to design probes
in pairs (one anchor and one sensor probe). This requirement can
cause somemutations to bemasked by the anchor probes (18) and
in some cases results in Tm differences that are less than 0.5°C
between wild-type and mutant sequences (25). FRET probes also
require the monitoring of fluorescence ratios, which generates
complicated Tm patterns that can be easily confounded by DNA
mixtures (20). A recent study used shared-stem molecular bea-
cons and TaqMan probes to identify rpoB RRDRmutations using
post-PCR Tm calculations (18). However, the assay required at
least two independent reactions and four different probes to cover
the entire RRDR. Furthermore, the Tm differences and the resolu-
tion provided by the shared-stem molecular beacons was much
smaller than that observedwith other dually labeled probes and by
our assay, decreasing mutant discriminatory capacity (18).
Mismatch-tolerant SMB probes created according to our de-
sign principles allow versatility in sequence recognition while
maintaining a robust capacity to discriminate mutations. The
three-point Tm code produced by our assay either specifically
identified RRDR mutations or grouped them into easily identifi-
able mutation clusters. This ability to subtype different RRDR
mutations may prove useful in epidemiological investigations or
where different rifamycins confer different levels of resistance (20,
28, 30, 35). The assay did not depend on high-resolution Tm ca-
pabilities. Unlike other assays which focus mainly on identifying
the most common clinically prevalent mutations (20, 24, 27), we
designed our assay to detect both the common and uncommon
mutations over the entire RRDR sequence. The large probe re-
gions permitted by SMB design made it possible for us to use just
three probes to target the entire 80-bp rpoB RRDR sequence. The
assay identified every type of mutation tested, including nucleo-
tide transitions, transversions, deletions, and insertions, along
with several double mutations.
There are some limitations to the current form of our assay.
First, our assay cannot specifically differentiate an infrequently
occurring synonymous mutation at RRDR codon 514 from non-
synonymous mutations at codon 514, which are associated with
rifampin resistance (13). Should synonymous mutations appear
more frequently than are currently reported in clinical settings,
our assay could be redesigned to generate a unique three-pointTm
code for that particular mutation. Second, the average dTm of the
rpo3 probe for the 533CCG mutant was 1.16°C. While sufficient
to reliably detect 533CCGmutations, this dTmwas the smallest of
all the dTms generated bymutations in our assay. It is possible that
the dTm for 533CCG mutations could be improved by additional
rounds of probe redesign. Third, we have not yet tested our assay
on DNA directly extracted from human sputum samples. It is
possible that PCR inhibitors present in sputum degrade the assay
LOD. However, many methods exist to extract M. tuberculosis
DNA from sputum for sensitive real-time PCR assays (3, 22).
Therefore, we do not expect this to be a major developmental
hurdle.
In summary, we have developed a sensitive, specific, and rapid
assay that is strongly amenable to a high-throughput format
which can detect all of the clinically significant mutations in the
rpoB RRDR of M. tuberculosis. This assay is specific for M. tuber-
culosis, simple, and robust and does not require any high-resolu-
FIG. 4. Detection of mixed-sequence heteroresistance. The assay was per-
formed with various mixtures of wild-type and mutant DNA, as indicated.
Double Tm peaks, indicating mixtures of wild-type and mutant target, were
seen when as little as 40% mutant sequence was present.
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tion melting software, thus it is compatible with various real-time
PCRplatforms. The SMBTm coding approachwe describe is likely
to be generally useful for rapid mutation detection in clinical mi-
crobiology.
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